Head-to-head evidence
BMS-986315 vs Monalizumab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: NKG2A · full Non-Small Cell Lung Cancer pipeline
BMS-986315
Developed by Bristol-Myers Squibb
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Monalizumab
Developed by MedImmune LLC and partners
NCT03822351 · Phase 2 · completed
Participants were randomized among three treatment arms, including 62 receiving durvalumab plus monalizumab and 67 receiving durvalumab alone, but the study was open-label rather than blinded. The primary clinical endpoint, RECIST 1.1 objective response at 16 weeks, was 40.3% with monalizumab plus durvalumab versus 23.9% with durvalumab alone; because statistical significance for this comparison was not reported, the result is considered unclear.
Next expected readout: April 2028 · NCT07146230 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: BMS-986315's landscape · Monalizumab's landscape